TGTX250502C37500
- 4.63
- +0.43+10.24%
TG Therapeutics Newsroom
TD Cowen Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $50
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $11
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $55
Buy Rating for TG Therapeutics Driven by Promising Briumvi Data and Strong Revenue Projections
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and TG Therapeutics (TGTX)
TG Therapeutics: Strategic Positioning and Growth Potential Drive Buy Rating
TD Cowen Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $50
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $53
A Quick Look at Today's Ratings for TG Therapeutics(TGTX.US), With a Forecast Between $10 to $55
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), BioLife Solutions (BLFS) and Surgery Partners (SGRY)
TG Therapeutics Analyst Ratings
Strong Financial Performance and Promising Outlook Drive Buy Rating for TG Therapeutics
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $10
Bank of America Securities Sticks to Its Sell Rating for TG Therapeutics (TGTX)
TD Cowen Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $50
TG Therapeutics Analyst Ratings
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $55
Strong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG Therapeutics
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $38
B.Riley Financial Reaffirms Their Buy Rating on TG Therapeutics (TGTX)